ArticleFrontiers in pharmacology2025
Hyperoside ameliorates lupus nephritis by suppressing AKT1-mediated PANoptosis in podocytes: integrating network pharmacology and experimental validation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN), one of the most common and severe complications of systemic lupus erythematosus (SLE), remains challenging to treat due to its complex pathogenesis. Hyperoside (Hyp), a naturally occurring flavonol glycoside and a key active component in numerous Chinese medicines and herbs, has demonstrated renoprotective effects via multiple signaling pathways, showing promise for LN treatment. However, its underlying mechanisms of renal protection in LN, particularly its regulatory potential on PANoptosis, remain unexplored. Objective: This study investigated the role of PANoptosis in LN pathogenesis, focusing on protein kinase B (AKT1) -mediated podocyte PANoptosis, to elucidate the therapeutic mechanism of Hyp. Methods: Potential Hyp targets were predicted using the SwissTargetPrediction database, while LN-related targets were retrieved from the GeneCards database. Overlapping targets were identified as potential key targets, and a Protein-Protein Interaction (PPI) network was constructed to screen core targets. GO and KEGG analyses of these overlapping targets were performed via the DAVID database to predict the mechanisms of Hyp against LN. Molecular docking between Hyp and the core target was conducted using AutoDock (Version 1.5.7) and visualized with PyMOL. Finally, Results: Network pharmacology and molecular docking analyses indicated that AKT1 is a core target shared by Hyp and LN, with Hyp exhibiting stable binding to AKT1. Experimental validation demonstrated that Hyp treatment inhibited podocyte PANoptosis and alleviated renal injury in MRL/lpr mice. Mechanistically, Hyp suppressed PANoptosis by modulating the PI3K/AKT axis. AKT1 overexpression attenuated the therapeutic effects of Hyp, confirming its pivotal role in LN pathogenesis. Conclusion: This study reveals that AKT1-mediated podocyte PANoptosis is a key mechanism in LN and establishes Hyp as a promising therapeutic agent targeting this pathway. These findings provide a novel and clinically translatable strategy for LN treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.